193 related articles for article (PubMed ID: 9933800)
1. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder.
Irani J; Desgrandchamps F; Millet C; Toubert ME; Bon D; Aubert J; Le Duc A
Eur Urol; 1999 Feb; 35(2):89-92. PubMed ID: 9933800
[TBL] [Abstract][Full Text] [Related]
2. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
[TBL] [Abstract][Full Text] [Related]
4. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
Gibanel R; Ribal MJ; Filella X; Ballesta AM; Molina R; Alcaraz A; Alcover JB
Anticancer Res; 2002; 22(2B):1157-60. PubMed ID: 12168917
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
6. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
Serretta V; Pomara G; Rizzo I; Esposito E
Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the BTA tests for the detection of bilharzial related bladder cancer: the Cairo experience.
Khaled HM; Abdel-Salam I; Abdel-Gawad M; Metwally A; El-Demerdash S; El-Didi M; Morsi A; Ishak L
Eur Urol; 2001 Jan; 39(1):91-4. PubMed ID: 11173945
[TBL] [Abstract][Full Text] [Related]
8. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E
Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097
[TBL] [Abstract][Full Text] [Related]
9. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
10. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
11. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test.
Raitanen MP; Hellström P; Marttila T; Korhonen H; Talja M; Ervasti J; Tammela TL;
Eur Urol; 2001 Oct; 40(4):422-6. PubMed ID: 11713397
[TBL] [Abstract][Full Text] [Related]
13. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer.
Oge O; Atsü N; Sahin A; Ozen H
Scand J Urol Nephrol; 2000 Dec; 34(6):349-51. PubMed ID: 11195897
[TBL] [Abstract][Full Text] [Related]
14. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
[TBL] [Abstract][Full Text] [Related]
17. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
[TBL] [Abstract][Full Text] [Related]
18. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
[TBL] [Abstract][Full Text] [Related]
19. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.
Thomas L; Leyh H; Marberger M; Bombardieri E; Bassi P; Pagano F; Pansadoro V; Sternberg CN; Boccon-Gibod L; Ravery V; Le Guludec D; Meulemans A; Conort P; Ishak L
Clin Chem; 1999 Apr; 45(4):472-7. PubMed ID: 10102906
[TBL] [Abstract][Full Text] [Related]
20. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder.
Heicappell R; Wettig IC; Schostak M; Müller M; Steiner U; Sauter T; Miller K
Eur Urol; 1999 Jan; 35(1):81-7. PubMed ID: 9933798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
